RxDoctor Payments Data

John Varner, DO

Cardiovascular Disease · Angola, INNPI 1770578338

Payments from drug & device makers

$610in general payments, 2019–2025

Across 29 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$169
  • AstraZeneca$89
  • Medtronic$86
  • Johnson & Johnson$39
  • Novartis$37
  • Amgen$35
  • plus $155 from 8 others

What the payments were for

  • Food & beverage$610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$610 in reported general payments places this provider in the 25th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$39,689
Medicare patients
451
Services billed
796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban255$312,168
XareltoRivaroxaban26$27,614
Diltiazem 24hr Er (Cd)Diltiazem Hcl75$1,860
Metoprolol Succinate126$1,158
Rosuvastatin Calcium107$1,060
Nebivolol Hcl13$928
Atorvastatin Calcium122$910
Flecainide Acetate16$831
Losartan Potassium85$596
Carvedilol88$530
Potassium Chloride26$481
Amiodarone Hcl19$471
Amlodipine Besylate84$373
ClopidogrelClopidogrel Bisulfate31$358
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide56$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$39$27,61426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Angola

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →